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In a previous publication (7) the authors mcli-
cated that a significant lowering of plasma potas-
sium values occurred concurrently with the clini-
cal improvement of treated psoriatic patients.
This preliminary study included 25 patients; the
series has now been extended to a total of 50
patients for the plasma potassium values and 20
patients for the cutaneous potassium values. In
addition to the potassium values in skin and
plasma, variations in plasma sodium, chloride,
alkaline reserve and glycemia occurring during
clinical improvement of psoriatics were also
measured.
Subjects
Our investigation was carried out in 50 patients
with psoriasis, 20 of which were women; and on 22
control patients 7 of which were women. The
age of the subjects varied from 18 to 77 with an
average age of 46. Twenty nine were between 30
and 55.
All but five of the patients were hospitalized.
The cases studied had lesions extensive enough
to hinder them in their daily life. This, and the
difficulties of ambulatory treatment, made
hospitalization acceptable to the patients.
Various clinical types were represented in this
series:
21 cases of generalized psoriasis with large
infiltrated plaques
8 cases of psoriasis of the extremities with
extension to palms and soles
7 cases of acute outbreak of generalized psoria-
sis "guttata"
6 cases of psoriatic erythroderma
4 cases of eczematized psoriasis
4 cases of "irritable" psoriasis developing dur-
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lag treatment new lesions in areas under-
going regression.
The disease had been present from 5 months to
50 years, with an average duration of 11 years.
In half the cases psoriasis had been present from
5 to 20 years.
Most of the patients were in a phase of exacer-
bation and had not been recently treated. At the
most, some of them had applied salicylated
petrolatum. The subjects, including the control
cases seemed to be free of any acute or chronic
disease liable to modify their mineral metabolism.
They received a normal and balanced diet.
Control8
These were both healthy subjects and patients
with dermatologic diseases other than psoriasis
who were being treated in a fashion similar to the
psoriatics.
Blood Samples
Heparinized fasting blood samples were drawn
in the morning by venous puncture. The plasma
was immediately separated by centrifugation
under paraffin oil The samples were taken on
each patient: 1) Once or twice before any local or
general treatment. 2) During the treatment when
clinical improvement became noticeable, or
definite. In general this was 8 to 20 days after the
beginning of the treatment, sometimes after a
longer delay. Each patient had at least three
blood samples taken during this period. 3) After
discharge when the patient had resumed normal
activity, whether improvement continued or
whether there was a recurrence.
Chemical Analysis of Plasma
Potassium and sodium values were deter-
mined by flame photometry; glucose, by Nelson's
method (10); chlorides, by Lestradet's modifica-
tion (6) of Seribner's method; alkaline reserve by
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Van Slyke's method. Each value was deter-
mined in duplicate and the results averaged.
Skin Samples
These were obtained by punch biopsy without
local procaine anesthesia after careful cleansing
of the skin with 90% alcohol and ether. The upper
areas of the buttocks or the thighs were generally
selected as biopsy sites. In the psoriatic subjects,
samples were taken from involved skin under
treatment, untreated involved skin, and unaf-
fected skin. In the control patients all samples
were taken from healthy skin. All biopsy speci-
mens were taken from comparable areas. The
skin specimens measured 5 mm in diameter and
consisted mainly of epidermis. Immediately after
removal of blood and fat their weight ranged
between 15 and 20 mg.
Chemical Analysis of Skin Samples
After drying, the skin samples were immersed
for 24 hours in 10 ml. of a 1 N HNO3 solution,
following Lowry and Hastings' technic (8). Potas-
sium and sodium were analyzed in this solution
by flame photometry.
Treatments Used
Topical therapy was in all cases varied and
determined by successive and comparative trials
in order to determine which substances were at
the same time most active and best tolerated
(15). The following external therapeutic agents
were used: Cignoline, Goudroline, Arning's
tincture, Salicylated petrolatum, Eosin, Ichthyol,
Pine tar, Trichloracetic acid, and Ultra violet
rays.
Internal therapy consisted primarily of seda-
tives (barbiturates or others). Some patients
receiving Vitamin B12, or sulfhydril aminoacids,
and a few cases were given delta-1-dehydro-
cortisone (Prednisone). However, in most eases
only topical treatment was used.
RESULTS
1. Variations in Cutaneous Potassium Values
A summary of cutaneous potassium values is
given in Table I. The mean values expressed in
milliequivalents of potassium per gram of skin
TABLE I
Potassium concentration in the skin of controls and
in the uninvolved, involved, and treated skin of
psoriatic patients
Skin Site Potassium
mEcijl000 g
Number
of
Biopsies
Controls
(16)
normal 19.2 0.79 16
Psoriatics
(20)
uninvolved
involved
lesion under
treatment
19.8 0.61
36.6 1.62
26.6 2.2
21
18
12
(wet weight) and the standard error of the mean*
were found to be:
19.2 0.79 in 16 controls,
19.8 0.61 in 21 samples from uninvolved
skin of psoriatic patients.
36.6 1.62 in 18 samples from involved, un-
treated psoriatic skin,
26.6 2.2 in 12 samples from psoriatic lesions
improving under treatment.
Thus it seems that skin taken from psoriatic
patients in uninvolved areas contains the same
amount of potassium as normal skin. However,
skin taken from psoriatic lesions contain 1.8
times as much potassium as normal skin. This
confirms the results obtained by Dörffel (4).
Clinical improvement of the lesions is ac-
companied by a significant lowering of its potas-
sium content.
Sodium skin levels taken in 10 cases of psoriasis
were not significantly different from normal skin
values.
2. Variations in Electrolytes and Glucose Levels in
the Plasma
A. Variations in Plasma Potassium. (Table II)
In 44 patients with active psoriasis lesions the
mean plasma potassium value was 4.56 0.17 m
Eq/liter. This does not differ from the value
* All the mean values are statistically analyzed.
The standard error of the mean is_computed as
follows: rn = \/(x — m)2/n(n — 1)
where x is the value of each sample, m the arith-
metical mean, n the number of samples. Compari-
son of means for significance of differences is
subjected to Student's t test, with t chosen for
95% confidence limits.
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TABLE II
Plasma levels of electrolytes and blood sugar in
psoriatic patients during active phase
and during clinical improvement
Sodium
(mEq/liter)
Chloride
(mEq/liter
TABLE III
Frequency of variations observed in plasma
electrolytes and blood sugar during
clinical improvement of psoriasis
Number
of Cases
Variation from Baseline
Established During
Activity of Psoriasis
In-
crease
Be-
crease
No
change
Potassium 44 5 81 8
Sodium 43 9 10 534
Chloride 23 2 16 5
Alkaline Reserve 16 10 1 5
Blood Sugar 26 6 12 6
Examination of the figures from the standpoint
of frequency of variation shows (Table III) that
among the 44 psoriatics who were improving
under treatment a significant lowering of plasma
potassium was observed in 31, a rise in 5, and no
change in 8. (To be significant we considered that
a change had to be greater than m Eq/
liter.)
obtained in the controls nor from generally ac-
cepted normal values. However the plasma potas-
sium level of patients during improvement of
lesions under treatment is noticeably lower:
3.98 0.13 m Eq/liter. This lowering seems to
be independent of the time elapsed since begin-
ning of treatment: in 24 patients who improved
between the 8th and the 15th day, potassium
values, were 3.98 0.13 m Eq/liter; in 23 pa-
tients who had maintained or increased their
recovery between the 16th and 60th day, potas-
sium values were 4.15 0.15 m Eq/liter.
It should be noted that when a drop in plasma
potassium occurs it is within the limits of physio-
logical variation, and seems to have nothing to do
with the age of the subject, the duration of the
psoriasis, nor the type of treatment used, but is
rather linked with clinical improvement.
In 14 patients when relapses occurred from 3 to
15 months after a first treatment a return of the
blood potassium level to approximately its
original value for each subject was observed. The
beginning of new and energetic treatment
brought with it a new drop in blood potassium.
No significant variations in plasma potassium
were observed under similar conditions among
the controls.
B. Variations in Plasma Sodium
As shown in Tables II and III it appears that
plasma sodium values do not vary significantly
under the conditions observed in this study.
Among 24 out of 43 cases, changes during clinical
improvement were less than m Eq/liter
in each case. Nine of the cases showed an in-
crease, and 10 showed a decrease.
C. Variations in Plasma Chloride
Chloride was analyzed in 23 cases of psoriasis
during improvement. In 16 patients there was a
significant lowering (greater than 1.7 m Eq/
liter) (Table III). The mean chloride values were
104.8 0.84 m Eq/liter before treatment and
101.15 0.73 m Eq/liter during clinical im-
provement (Table II).
D. Variations in Alkaline Reserve
Ten out of 16 cases studied displayed a sig-
nificant increase (more than 1.6 m Eq/liter) dur-
ing clinical improvement. Five showed no change,
and 1 a decrease. Initial mean value was 25.8
0.73 m Eq/liter; this increased to 28.9 0.81 m
Eq/liter during improvement.
Potassium
(mEq/liter)
During Active During Clinical
Psoriasis Improvement
4.58±0.17 (61)* 3.98±0.15 (89)
139.5±1.32 (58) 141.2±1.22 (81)
104.8±0.84 (29) 101.1±0.73 (35)
25.8±0.73 (17) 28.9±0.81 (22)
0.87±0.07 (28) 0.77±0.05 (36)
Alkaline re-
serve
(mEq/liter)
Blood sugar
(g/liter)
* Figures in parenthesis refer to the number of
observations.
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E. Variations in Blood Glucose
Changes occurring during improvement were
neither constant nor significant (see Tables II
and III).
DiscussIoN
It is evident that the variations observed are
not due to chance only. In addition, examination
of the results show that age, sex, duration and
form of treatment have no influence in the varia-
tions of values reported in this study. There is a
definite correlation between clinical improve-
ment of psoriasis and changes in skin potassium
and in plasma potassium, chloride and alkaline
reserve. This leads us to believe that important
metabolic changes take place during improve-
ment.
In all of our cases clinical improvement was
obtained through energetic topical therapy;
internal therapy produced spotty and irregular
results. Therefore it is primarily the local skin
changes which we should attempt to explain, and
here most of all the accumulation of potassium in
lesions of psoriasis. This finding, mentioned
previously by Dörffel (4), is probably due to the
acanthosis and the abundance of young epidermal
cells in psoriatic lesions, (Rothman, (14)). We
know that any active cellular proliferation (as in
certain neoplastic tissues for instance) is ac-
companied by an increase in potassium content
(12). Psoriatic lesions are no exception to this
rule and in this sense the accumulation of potas-
sium cannot be considered specific for psoriasis.
But since it is generally accepted that potassium
is indispensable to the anabolism of proteins (2,
11) and carbohydrates (16, 13) and hence to the
cell structure one may conceive that it plays an
important role in the psoriatic lesion. At the
same time it may be possible that by diminishing
the potassium content of psoriatic lesions their
proliferating capacity may be decreased, like
that of any other tissue rich in potassium.
The egress of potassium ions from cells can be
related to an increase in hydrogen ions in these
cells (5, 3), whatever the cause for this increase in
hydrogen ions may be (glycolysis, direct corti-
costeroid action, etc.). Therefore one may suppose
that the clinical improvement observed in pa-
tients with psoriasis is the result, among others,
of a gain in hydrogen ions and a loss in potassium
ions of the involved tissues. The fact that the
topically active substances in psoriasis for the
most part are strong reducing agents (tars, oil of
cade, chrysarobin, cignolin, anthrarobin, etc.)
and certain topically applied acids (15) may be
cited in support for this hypothesis. Thus the
humoral changes found during the clinical im-
provement of psoriatic lesions could result from
the local treatment and the skin changes; it is well
known (3) that hypopotassemia associated with
hypochioremia and alkalosis may be associated
with a loss of potassium ions and a gain of hydro-
gen ions by the tissues.
A second hypothesis should also be considered:
namely that the cutaneous changes are the result
of primary humoral changes. The tendency
toward hypopotassemia and alkalosis brings to
mind the possibility of an increased adreno-
cortical secretion, more particularly of aldoster-
one. If such were the case, sodium retention and
eventually weight gain and increased blood pres-
sure should be observed. None of our cases showed
these symptoms, although it must be said that an
increased sodium level may be compensated by a
larger blood volume and extracellular fluid; these
findings have been noted during the progression
of some cases of psoriasis (9, 17). However,
attempts at treatment by parenteral corticoste-
roids or ACTH have failed in the majority of
cases. Aldosterone levels were not determined in
our patients and it is not known whether an
increased secretion of this hormone is or is not
present.
In five of our patients we followed the daily
urinary output, the glomerular filtration rate
(creatiine clearance), and the excretion of potas-
sium, sodium and chloride. No significant varia-
tions were found but it should be noted that the
food intake was only relatively constant, the
daily potassium intake varying from 75 to 90
m Eq.
Finally, therapeutic trials aiming at increasing
potassium loss either locally (reverse iontophore-
sis (1)) or by systemic means (with Diamox, a
carbonic anhydrase inhibitor or with ammonium
chloride) have not given satisfactory results.
SUMMARY
1) Skin potassium levels in 20 patients with
psoriasis were normal in uninvolved skin and very
high in the lesions. This disturbance decreased
when clinical improvement took place under
treatment.
2) Plasma potassium, sodium chloride and
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alkaline reserve were normal in psoriatic patients
during the active phase of the disease. During
clinical improvement the following changes from
initial values were observed:
a lowering of plasma potassium in 31 out of 44
cases.
a lowering of plasma chloride in 16 out of 23
cases.
an increase of alkaline reserve in 10 out of 16
cases.
These changes were statistically significant
although the values remained within physio..
logically normal limits.
3) Plasma sodium and glucose did not vary
significantly during clinical improvement.
4) The cutaneous changes observed may be due
to competition between potassium and hydrogen
ions resulting from the metabolic effects of topical
application of strong reducing or acid substances.
5) The humoral changes observed may result
from the local treatment; present data do not
give any clue regarding a possible increase in
adrenocortical activity.
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